QQQ   321.97 (+2.49%)
AAPL   126.41 (+4.25%)
MSFT   236.33 (+1.70%)
FB   262.30 (+1.82%)
GOOGL   2,060.43 (+1.91%)
TSLA   706.36 (+4.57%)
AMZN   3,124.26 (+1.01%)
NVDA   546.10 (-0.45%)
BABA   240.27 (+1.06%)
CGC   34.74 (+6.08%)
GE   13.20 (+5.26%)
MU   94.00 (+2.70%)
NIO   49.42 (+7.95%)
AMD   85.73 (+1.44%)
T   28.25 (+1.29%)
F   11.97 (+2.31%)
ACB   11.17 (+6.18%)
DIS   194.83 (+3.06%)
BA   223.48 (+5.41%)
NFLX   546.93 (+1.50%)
BAC   35.86 (+3.31%)
QQQ   321.97 (+2.49%)
AAPL   126.41 (+4.25%)
MSFT   236.33 (+1.70%)
FB   262.30 (+1.82%)
GOOGL   2,060.43 (+1.91%)
TSLA   706.36 (+4.57%)
AMZN   3,124.26 (+1.01%)
NVDA   546.10 (-0.45%)
BABA   240.27 (+1.06%)
CGC   34.74 (+6.08%)
GE   13.20 (+5.26%)
MU   94.00 (+2.70%)
NIO   49.42 (+7.95%)
AMD   85.73 (+1.44%)
T   28.25 (+1.29%)
F   11.97 (+2.31%)
ACB   11.17 (+6.18%)
DIS   194.83 (+3.06%)
BA   223.48 (+5.41%)
NFLX   546.93 (+1.50%)
BAC   35.86 (+3.31%)
QQQ   321.97 (+2.49%)
AAPL   126.41 (+4.25%)
MSFT   236.33 (+1.70%)
FB   262.30 (+1.82%)
GOOGL   2,060.43 (+1.91%)
TSLA   706.36 (+4.57%)
AMZN   3,124.26 (+1.01%)
NVDA   546.10 (-0.45%)
BABA   240.27 (+1.06%)
CGC   34.74 (+6.08%)
GE   13.20 (+5.26%)
MU   94.00 (+2.70%)
NIO   49.42 (+7.95%)
AMD   85.73 (+1.44%)
T   28.25 (+1.29%)
F   11.97 (+2.31%)
ACB   11.17 (+6.18%)
DIS   194.83 (+3.06%)
BA   223.48 (+5.41%)
NFLX   546.93 (+1.50%)
BAC   35.86 (+3.31%)
QQQ   321.97 (+2.49%)
AAPL   126.41 (+4.25%)
MSFT   236.33 (+1.70%)
FB   262.30 (+1.82%)
GOOGL   2,060.43 (+1.91%)
TSLA   706.36 (+4.57%)
AMZN   3,124.26 (+1.01%)
NVDA   546.10 (-0.45%)
BABA   240.27 (+1.06%)
CGC   34.74 (+6.08%)
GE   13.20 (+5.26%)
MU   94.00 (+2.70%)
NIO   49.42 (+7.95%)
AMD   85.73 (+1.44%)
T   28.25 (+1.29%)
F   11.97 (+2.31%)
ACB   11.17 (+6.18%)
DIS   194.83 (+3.06%)
BA   223.48 (+5.41%)
NFLX   546.93 (+1.50%)
BAC   35.86 (+3.31%)
Log in
NASDAQ:LQDA

Liquidia Stock Forecast, Price & News

$2.94
+0.14 (+5.00 %)
(As of 03/1/2021 01:55 PM ET)
Add
Compare
Today's Range
$2.85
Now: $2.94
$3.00
50-Day Range
$2.74
MA: $3.10
$3.60
52-Week Range
$2.53
Now: $2.94
$12.10
Volume28,974 shs
Average Volume1.67 million shs
Market Capitalization$127.41 million
P/E RatioN/A
Dividend YieldN/A
Beta0.05
Liquidia Corporation, through its subsidiaries, operates as a late-stage clinical biopharmaceutical company. The company focuses on the development and commercialization of various products using its PRINT technology that enables precise production of drug particles designed to enhance the safety, efficacy, and performance of a range of therapies. Its product candidates include LIQ861 for the treatment of pulmonary arterial hypertension; and LIQ865 for the treatment of local post-operative pain. The company also provides strategy, investment, and commercialization services for rare disease pharmaceutical products, such as generic Remodulin, a parenteral formulation of treprostinil for pulmonary arterial hypertension. Liquidia Corporation was founded in 2004 and is based in Morrisville, North Carolina.
Liquidia logo

Headlines

LQDA Jan 2021 12.500 put
December 23, 2020 |  au.finance.yahoo.com
LQDA Jan 2021 7.500 call
December 22, 2020 |  au.finance.yahoo.com
See More Headlines

Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:LQDA
CUSIPN/A
CIKN/A
Phone(919) 328-4400
Employees64
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$8.07 million
Book Value$1.24 per share

Profitability

Net Income$-47,580,000.00

Miscellaneous

Market Cap$127.41 million
Next Earnings Date3/10/2021 (Estimated)
OptionableNot Optionable

MarketRank

Overall MarketRank

1.47 out of 5 stars

Medical Sector

489th out of 1,965 stocks

Surgical & Medical Instruments Industry

50th out of 169 stocks

Analyst Opinion: 3.4Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 0.6 5 -4 -3 -2 -1 -
$2.94
+0.14 (+5.00 %)
(As of 03/1/2021 01:55 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive LQDA News and Ratings via Email

Sign-up to receive the latest news and ratings for LQDA and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Liquidia (NASDAQ:LQDA) Frequently Asked Questions

Is Liquidia a buy right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Liquidia in the last year. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Liquidia stock.
View analyst ratings for Liquidia
or view top-rated stocks.

What stocks does MarketBeat like better than Liquidia?

Wall Street analysts have given Liquidia a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Liquidia wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Liquidia?

Liquidia saw a decrease in short interest in January. As of January 15th, there was short interest totaling 1,190,000 shares, a decrease of 12.5% from the December 31st total of 1,360,000 shares. Based on an average daily volume of 1,170,000 shares, the days-to-cover ratio is currently 1.0 days.
View Liquidia's Short Interest
.

When is Liquidia's next earnings date?

Liquidia is scheduled to release its next quarterly earnings announcement on Wednesday, March 10th 2021.
View our earnings forecast for Liquidia
.

How were Liquidia's earnings last quarter?

Liquidia Co. (NASDAQ:LQDA) released its earnings results on Thursday, November, 12th. The company reported ($0.40) EPS for the quarter, missing the consensus estimate of ($0.37) by $0.03.
View Liquidia's earnings history
.

How has Liquidia's stock been impacted by COVID-19 (Coronavirus)?

Liquidia's stock was trading at $3.66 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, LQDA stock has decreased by 18.9% and is now trading at $2.97.
View which stocks have been most impacted by COVID-19
.

What price target have analysts set for LQDA?

4 equities research analysts have issued twelve-month price targets for Liquidia's shares. Their forecasts range from $4.00 to $40.00. On average, they expect Liquidia's stock price to reach $18.50 in the next year. This suggests a possible upside of 522.9% from the stock's current price.
View analysts' price targets for Liquidia
or view top-rated stocks among Wall Street analysts.

Who are Liquidia's key executives?

Liquidia's management team includes the following people:
  • Mr. Robert A. Lippe, Chief Operations Officer (Age 56, Pay $593.73k)
  • Mr. Damian deGoa, CEO & Director (Age 43)
  • Mr. William R. Kenan Jr., Co-Founder
  • Dr. Ginger Denison, Co-Founder
  • Mr. Michael Kaseta, Chief Financial Officer (Age 45)
  • Jennifer Almond, Director of Investor Relations & Corp. Communications
  • Shawn Glidden, VP of Legal Affairs & Sec.
  • Mr. Jason Adair, VP of Corp. Devel. & Strategy (Age 48)
  • Ms. Florina Gordon-Krawchick, Sr. VP of HR (Age 39)
  • Dr. Tushar Shah M.D., Chief Medical Officer (Age 61)

Who are some of Liquidia's key competitors?

What other stocks do shareholders of Liquidia own?

When did Liquidia IPO?

(LQDA) raised $50 million in an IPO on Thursday, July 26th 2018. The company issued 4,500,000 shares at a price of $10.00-$12.00 per share. Jefferies and Cowen served as the underwriters for the IPO and Needham & Company and Wedbush PacGrow were co-managers.

What is Liquidia's stock symbol?

Liquidia trades on the NASDAQ under the ticker symbol "LQDA."

Who are Liquidia's major shareholders?

Liquidia's stock is owned by a variety of institutional and retail investors. Top institutional investors include BlackRock Inc. (4.93%), Ikarian Capital LLC (2.20%), Northern Trust Corp (0.71%), Nuveen Asset Management LLC (0.21%), Bank of New York Mellon Corp (0.20%) and Wells Fargo & Company MN (0.12%). Company insiders that own Liquidia stock include Eshelman Ventures, Llc and Timothy Albury.
View institutional ownership trends for Liquidia
.

Which major investors are selling Liquidia stock?

LQDA stock was sold by a variety of institutional investors in the last quarter, including Sigma Planning Corp, Barclays PLC, and Nuveen Asset Management LLC.
View insider buying and selling activity for Liquidia
or view top insider-selling stocks.

Which major investors are buying Liquidia stock?

LQDA stock was purchased by a variety of institutional investors in the last quarter, including Ikarian Capital LLC, BlackRock Inc., Clear Harbor Asset Management LLC, Philadelphia Trust Co., Wells Fargo & Company MN, Bank of New York Mellon Corp, ExodusPoint Capital Management LP, and Northern Trust Corp.
View insider buying and selling activity for Liquidia
or or view top insider-buying stocks.

How do I buy shares of Liquidia?

Shares of LQDA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Liquidia's stock price today?

One share of LQDA stock can currently be purchased for approximately $2.97.

How much money does Liquidia make?

Liquidia has a market capitalization of $128.71 million and generates $8.07 million in revenue each year. The company earns $-47,580,000.00 in net income (profit) each year or ($2.59) on an earnings per share basis.

How many employees does Liquidia have?

Liquidia employs 64 workers across the globe.

What is Liquidia's official website?

The official website for Liquidia is www.liquidia.com.

Where are Liquidia's headquarters?

Liquidia is headquartered at 419 DAVIS DRIVE SUITE 100, MORRISVILLE NC, 27560.

How can I contact Liquidia?

Liquidia's mailing address is 419 DAVIS DRIVE SUITE 100, MORRISVILLE NC, 27560. The company can be reached via phone at (919) 328-4400 or via email at [email protected]


This page was last updated on 3/1/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.